Humanigen, Inc. (HGENQ)
Jul 15, 2024 - HGENQ was delisted (reason: shares cancelled)
0.0002
0.00 (0.00%)
Inactive · Last trade price on Jul 11, 2024

Company Description

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response.

The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH.

It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis.

In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations.

Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct.

Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey. On January 3, 2024, Humanigen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Humanigen, Inc.
Humanigen logo
CountryNJ
Founded2000
IPO DateJan 31, 2013
IndustryBiotechnology
SectorHealthcare
Employees6
CEODr. Cameron Durrant M.D., MBA

Contact Details

Address:
830 Morris Turnpike, 4th Floor
Short Hills, New Jersey 07078
Phone(973) 200-3100
Websitehumanigen.com

Stock Details

Ticker SymbolHGENQ
ExchangeOTCMKTS
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001293310
CUSIP Number444863104
ISIN NumberUS4448632038
Employer ID77-0557236
SIC Code2834

Key Executives

NamePosition
Dr. Cameron Durrant M.D., MBAChairman, Chief Executive Officer, Principal Financial and Accounting Officer
Dr. Dale Chappell M.B.A., M.D., MBAChief Scientific Officer and Director
Robert Atwill M.B.A.Senior Vice President and Head of Asia-Pacific Region and Business Development
Edward P. Jordan M.B.A.Chief Commercial Officer

Latest SEC Filings

DateTypeTitle
Jan 8, 20248-KCurrent Report
Oct 12, 202325-NSEFiling
Sep 14, 20238-KCurrent Report
Aug 14, 2023NT 10-QNotification of inability to timely file Form 10-Q or 10-QSB
Jul 25, 20238-KCurrent Report
May 15, 202310-QQuarterly Report
Apr 25, 202310-K/A[Amend] Annual report
Apr 19, 20238-KCurrent Report
Apr 6, 20238-KCurrent Report
Mar 30, 202310-KAnnual Report